0001209191-19-038018.txt : 20190619 0001209191-19-038018.hdr.sgml : 20190619 20190619162333 ACCESSION NUMBER: 0001209191-19-038018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190618 FILED AS OF DATE: 20190619 DATE AS OF CHANGE: 20190619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LYNCH DANIEL CENTRAL INDEX KEY: 0001177082 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 19906303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-18 0 0001693415 Translate Bio, Inc. TBIO 0001177082 LYNCH DANIEL C/O TRANSLATE BIO, INC. 29 HARTWELL AVE LEXINGTON MA 02421 1 0 0 0 Stock Option (right to buy) 10.20 2019-06-18 4 A 0 18900 0.00 A 2029-06-17 Common Stock 18900 18900 D This stock option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. /s/ Paul Burgess, as attorney in fact for Daniel S. Lynch 2019-06-19